In this edition, smoking cessation support uptake at lung cancer screenings, glecirasib may deliver 'efficacy and tolerability advantages' and more. Read the full coverage here: Uptake of smoking cessation support high when offered at lung cancer screening Glecirasib may deliver 'efficacy and tolerability advantages' for KRAS-mutant lung cancer 'Substantial geographic disparities' worsening in cancer clinical trial availability Deployed military personnel have increased silica in lung tissue FDA approves Alecensa for certain patients with ALK-positive lung cancer References: Lowers H, et al. Int J Environ Res Public Health. 2024;doi:10.3390/ijerph21010091.Press Release Murray RL, et al. Eur Respir J. 2024;doi:10.1183/13993003.01768-2023. Press Release Sekar RR, et al. JAMA Netw Open. 2024;doi:10.1001/jamanetworkopen.2024.10162. Shi Y, et al. Abstract 468214. Presented at: ASCO Plenary Series; April 30, 2024.

Ver todos los episodios